Independently, Metzgeroth et al. reported limited clinical activity of sorafenib and nilotinib in T674I FIP1L1-PDGFRα-positive CEL patients [14]. This evidence concerns the gene FIP1L1 and Chronic Eosinophilic Leukemia, Not Otherwise Specified.